News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
UCB Group to Launch Epilepsy Drug in Autumn
June 27, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BRUSSELS, June 27 (Reuters) - Shares in UCB SA jumped on Friday as the Belgian pharmaceutical group said it aimed to launch its new epilepsy drug Vimpat in the autumn, after winning a green light from the European Medicines Agency.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Layoffs
Layoffs From Just 6 Pharmas Could Wipe Out Over 39,000 Jobs
September 18, 2025
·
9 min read
·
Angela Gabriel
PODCAST
What Do AI and Hammers Have in Common?
September 18, 2025
·
1 min read
·
Lori Ellis
CDC
Republicans Ratchet Up Pressure as Monarez Levels Damning Allegations Against Kennedy
September 17, 2025
·
4 min read
·
Heather McKenzie
FDA
FDA’s Ad Crackdown Targets Novo, Lilly’s Oprah Special on GLP-1s
September 17, 2025
·
3 min read
·
Annalee Armstrong
